NovelStem Reports Q1 2025 Financials: Losses Improve Amid Ongoing Operational Challenges

NovelStem International Corp. (PINK: NSTM) reported its quarterly financials for the period ending March 31, 2025. The company, involved primarily in biotech through its investments in NewStem Ltd. and NetCo Partners, continues to face significant operational and financial challenges.

Positive Aspects:

• General and administrative expenses decreased to $94,574 compared to $183,306 in Q1 2024, representing a drop of $88,732.
• Net loss for Q1 2025 was $207,216, improved from $303,280 in Q1 2024, marking a positive movement of $96,064.
• No administrative fee income was recorded, which is less concerning due to lower operational expenses.

Negative Aspects:

• Total assets decreased to $149,987 from $160,111, indicating a decline in asset base.
• Current liabilities rose to $5,492,837 from $5,304,486, driven mainly by interest accrued on debt and advances on short-term borrowings.
• The company continues to experience an accumulated deficit of approximately $296 million, impacting its ability to attract new financing effectively.
• No revenues have been generated from NewStem due to its liquidation process, severely limiting growth prospects.

Key Statistics:

• Administrative fee income: $0 (down from $3,000 in Q1 2024)
• Net loss per share: $(0.00) (basic and diluted)
• Cash at the end of the period: $3,401 (down from $6,099 as of December 31, 2024)
• Current assets: $21,747 (down from $31,871)
• Total liabilities: $5,492,837 (up from $5,304,486)
• Common stock outstanding: 46,881,475 shares

The company remains critically dependent on raising additional capital, with plans to sell its interest in NetCo to address its liabilities. Despite recent operational cost reductions, the overarching situation poses significant risks to continued operations and highlights the urgent need for effective strategic management. Continued monitoring of financial performance and operational adjustments will be essential in the coming quarters.